13 results about "Neuroglial cells" patented technology

Described herein are methods and compositions for treating a disease, e.g. cancer (including solid tumors), using glial cells (e.g. microglia cells and / or astrocytes) and / or macrophages (e.g., CNS-associated macrophages) infected with an oncolytic virus (e.g., vaccinia virus). The methods and compositions provided herein demonstrate a synergistic anti-cancer effect.

The application discloses a lactobacillus rhamnosus capable of significantly increasing the number of enteric neurons and neuroglial cells and an application thereof, and belongs to the field of microorganisms.The lactobacillus rhamnosus CCFM1360 has good activity, certain acid and alkali resistance and adhesion, can significantly increase the number of enteric neurons and neuroglial cells, repair intestinal barrier function, increase the content of SCFAs in colon contents, increase the number of Treg cells in mesenteric lymph nodes, reduce the expression level of inflammatory factors in colon tissues, reduce the intestinal inflammation level, and relieve the weakened intestinal motility disorder.

The invention discloses a composition for enhancing memory and improving cognitive function and application. The composition disclosed by the invention comprises acanthopanax, ginseng, Chinese wolfberry fruits, gastrodia elata, spina date seeds, poria cocos, Chinese yams, lotus seeds, gordon euryale seeds, mulberries, longan pulp, fresh ginger, walnut powder, egg protein powder, blueberry powder, raspberry powder, pumpkin seed powder, oat powder, spirulina powder, dark chocolate powder, a vitamin B group compound, gamma-aminobutyric acid, galactooligosaccharide and citric acid. According to the invention, a multi-channel and multi-target collaborative network is constructed by taking acanthopanax senticosus as a core, through multiple channels such as nerve regeneration, energy metabolism, oxidative stress, signal transduction, endocrine regulation and the like, different nodes such as neurons, neuroglial cells, cerebrovascular endothelium and the like are targeted, the overall optimization of the memory function is realized on the system level, and the memory function is optimized. The core idea of systematic biology of overall regulation and control is reflected, and the composition prepared from the composition has the effects of improving memory, learning ability and cognitive ability.

This invention belongs to the field of biology and discloses a method for co-culturing enteric glial cells (EGCs) and intestinal organoids. Primary cultured and purified enteric glial cells are digested and seeded onto the membrane of a Transwell chamber. Intestinal organoids are placed in individual Matrigel drops in a co-culture plate. The Transwell chambers are placed in the co-culture plate, and growth medium is added to ensure free exchange of the growth medium through the Transwell membrane. The EGC-organoid co-culture system obtained based on this method provides a model for studying diarrhea and intestinal health in large mammals. It also lays the research foundation for developing innovative intervention strategies targeting the enteric nervous system and provides a research model for further exploring the regulatory roles of nutrients or related genes in intestinal health.

The invention relates to a liquid dressing for skin and a preparation method of the liquid dressing. A film forming material of the liquid dressing comprises glial cell supernate. The neuroglial cells used in the invention are derived from neural stem cells which have been subjected to long-term in-vitro culture amplification, so that the obtained culture supernatant has the advantages of large scale, stable quality and mature technology, and a large number of liquid dressing products with stable and consistent quality standards can be provided in a short time; meanwhile, the supernate has good film-forming property and safety, contains a large number of human cell active components which are good in human body compatibility and beneficial to wound healing, and is suitable for large-scale batch production and application.

The application discloses a bifidobacterium that can significantly improve the expression of BDNF of a host and an application thereof, and belongs to the technical field of microorganisms. The bifidobacterium CCFM1359 provided by the application can effectively improve the levels of BDNF and its specific receptor TrkB in the colon of a mouse, can also increase the number of enteric glial cells, improve the content of excitatory neurotransmitter Ach in the colon, down-regulate the content of inhibitory neurotransmitter NO, and repair the enteric nervous system. Moreover, the bacteria can down-regulate the gene expression levels of TLR2 and TNF-alpha, up-regulate the gene expression level of IL-10, reduce the inflammation level in the colon, and regulate the intestinal motility. Therefore, in the future, a more personalized treatment scheme can be adopted for patients with damaged enteric nerves (including but not limited to intestinal motility disorders), and the application prospect is very considerable.

This invention relates to a liquid dressing for skin and its preparation method. The film-forming material of the liquid dressing comprises glial cell supernatant. The glial cells used in this invention are derived from neural stem cells that have achieved long-term in vitro culture and expansion. This allows for the production of culture supernatant with advantages such as large-scale production, stable quality, and mature technology. It can provide a large quantity of liquid dressing products with consistent quality standards in a short time. Furthermore, the supernatant exhibits good film-forming properties and safety, and contains a large number of biocompatible, wound-healing, and bioactive human cell components, making it suitable for large-scale mass production and application.

The invention discloses application of ergothioneine in promoting neural function recovery after spinal cord injury. The new application of the ergothioneine comprises inhibiting senescence of tissues or cells in a central nervous system after spinal cord injury, treating mitochondrial dysfunction of glial cells after spinal cord injury, promoting spinal cord injury repair and inhibiting spinal cord tissue inflammation after spinal cord injury. The invention reveals for the first time that ergothioneine significantly promotes spinal nerve regeneration, improves neurological functions, alleviates inflammatory response after aging and protects spinal cord tissues by regulating immune cell mitochondrial function-cell aging axis, and provides an innovative strategy for spinal cord injury treatment. The ergothioneine synergistically intervenes in secondary neurodegenerative diseases after spinal cord injury by protecting mitochondrial functions and immune dual pathways, and a brand new direction is provided for SCI treatment.

A chimeric non-human mammal disease model, wherein (1) at least 30% of all the glial cells in the corpus callosum of the chimeric non-human mammal are human glial cells, and / or (2) at least 5% of all of the glial cells in the white matter of the brain and / or brain stem of the chimeric non-human mammal are human glial cells, and wherein the human glial cells comprise a combination of a first group of human glial cells tagged with a first label and a second group of human glial cells tagged with a second label that is distinguishable from the first label.

The present invention provides compositions and methods for inhibiting the autoimmune component of neurodegenerative diseases and thereby providing a therapeutic effect to patients suffering from such diseases. The compositions and methods comprise immunosuppressive moieties, such as regulatory T cells (Tregs) and proteins expressed by Tregs coupled to a chimeric antigen receptor or that specifically bind to one or more glial cell markers. Therapeutically effective doses of the compounds for treating neurodegenerative diseases, including progressive supranuclear palsy (PSP), Parkinson's disease (PD), Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), chronic traumatic encephalopathy (CTE), and prion diseases, are disclosed.

The present invention provides compositions and methods for inhibiting the autoimmune component of neurodegenerative diseases and thereby providing a therapeutic effect to patients suffering from such diseases. The compositions and methods comprise immunosuppressive moieties, such as regulatory T cells (Tregs) and proteins expressed by Tregs coupled to a chimeric antigen receptor or proteins that specifically bind to one or more glial cell markers. Therapeutically effective doses of the compounds for treating neurodegenerative diseases, including progressive supranuclear palsy (PSP), Parkinson's disease (PD), Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), chronic traumatic encephalopathy (CTE), and prion diseases, are disclosed.

A chimeric non-human mammal disease model, wherein (1) at least 30% of all the glial cells in the corpus callosum of the chimeric non-human mammal are human glial cells, and / or (2) at least 5% of all of the glial cells in the white matter of the brain and / or brain stem of the chimeric non-human mammal are human glial cells, and wherein the human glial cells comprise a combination of a first group of human glial cells tagged with a first label and a second group of human glial cells tagged with a second label that is distinguishable from the first label.